TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06571669: BOOM-IBD2 Pivotal Clinical Trial

Sponsor: Boomerang Medical · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 137 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,277,000

Rescue Site Savings

+$1,518,000

Unlock Full NCT06571669 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06571669 Rescue Dossier →